Breaking News...Alzheimer's Drug That Showed Cognitive Decline Gets FDA Approval
Published 1/6/23 Washington Post.
"The Food and Drug Administration approved an Alzheimer’s drug that slowed cognitive decline in a major study, offering patients desperately needed hope — even as doctors sharply debated the safety of the drug and whether it provides a significant benefit. The FDA said the drug, called lecanemab, is for patients with mild cognitive impairment or early dementia because of Alzheimer’s. The accelerated approval was based on a mid-stage trial that showed the treatment effectively removed a sticky protein called amyloid beta — considered a hallmark of the illness — from the brain.
A larger trial, conducted more recently, found the drug, which will be sold under the brand name Leqembi, slowed the progression of Alzheimer’s disease by 27 percent."